Molecular Partners (NASDAQ:MOLN) Posts Earnings Results, Beats Estimates By $0.08 EPS

Molecular Partners (NASDAQ:MOLN) issued its quarterly earnings results on Thursday. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.46) by $0.08, Zacks reports.

Molecular Partners Price Performance

MOLN stock traded up $0.10 during mid-day trading on Friday, reaching $3.63. The company had a trading volume of 1,523 shares, compared to its average volume of 4,315. The company has a market capitalization of $146.74 million, a PE ratio of -2.13 and a beta of 1.11. The firm has a 50 day moving average of $4.05 and a 200 day moving average of $4.18. Molecular Partners has a 12 month low of $3.51 and a 12 month high of $5.36.

Analyst Upgrades and Downgrades

MOLN has been the subject of several recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Molecular Partners in a research report on Friday, October 2nd. HC Wainwright restated a “buy” rating on shares of Molecular Partners in a report on Monday, July 6th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Molecular Partners has an average rating of “Hold” and a consensus target price of $8.38.

About Molecular Partners

Molecular Partners AG is a clinical-stage biotechnology company headquartered in Schlieren, Switzerland. The company develops therapeutic molecules based on its proprietary DARPin platform, which uses designed ankyrin repeat proteins to create targeted, multi-specific medicines intended to address complex disease pathways.

Molecular Partners’ research and development activities have focused primarily on oncology, ophthalmology and infectious diseases. Its pipeline has included experimental programs designed to engage multiple biological targets, with the goal of improving treatment effectiveness and addressing limitations associated with conventional antibody-based therapies.